CHAPTER 11
Interviews with Private Equity Compliance Professionals

Throughout this book we have incorporated practical real-world examples of the implementation of compliance policies and procedures in private equity funds. This has been completed by case studies in regulatory actions related to private equity general partner (GP) and fund-level compliance. To continue this practical focus, this chapter provides interviews with three leading private equity professionals on trends and best practices in global private equity compliance.

11.1 BIOGRAPHY AND INTERVIEW WITH DR. THOMAS MEYER

Dr. Thomas Meyer's focus is the development of risk measurement models and investment strategies for private equity funds, funds-of-funds, and institutional investment programs. Related to this, he has years of practical experience and has researched and published on public policy approaches to the development of venture capital markets. Thomas is a member of the Risk Management for Alternative Investment Funds (AIFs) Working Group, of ALFI (Association of the Luxembourg Fund Industry), and of the Private Equity Fund Risk Measurement Guidelines Working Group of Invest Europe (former EVCA, European Venture Capital and Private Equity Association).

After 12 years in the German Air Force he worked for the German insurance group Allianz AG in corporate finance and as the regional chief financial officer of Allianz Asia Pacific in Singapore. He was responsible for the creation of the risk management function at the European Investment Fund (EIF). Thomas was a director of the European Private Equity and Venture Capital Association. He is a member of the private equity subcommittee of the Chartered Alternative Investment Analyst® Program.

Thomas authored Private Equity Unchained: Strategy Insights for the Institutional Investor (Palgrave MacMillan) and co-authored Beyond the J Curve (also translated in Chinese and in Japanese), J Curve Exposure, and Mastering Illiquidity (all John Wiley & Sons), and two Chartered Alternative Investment Analyst (CAIA) Level II books, the required readings of level II of the Chartered Alternative Investment Analyst Program.

Thomas studied computer science at the Bundeswehr Universität in Munich and holds a Dr. rer. nat. from the University of Trier. He graduated with an MBA from the London Business School and with an MA in Japanese Language and Society from the University of Sheffield's School of East Asian Studies. He was a visiting researcher at Hitotsubashi University in Tokyo and the Development Bank of Japan's Research Institute of Capital Formation. Thomas is a Shimomura Fellow of the Development Bank of Japan.

Jason Scharfman On a global basis, do you feel that private equity funds are subject to an appropriate amount of global regulation? Or instead are they overregulated (or underregulated)? Why do you come to this assessment?
Thomas Meyer To avoid any misunderstanding, I agree with the objective that all parts of the financial system need to be regulated. However, when it comes to alternative assets I question whether regulators (in consultation with the financial industry) have taken the right direction. The choices made have resulted in contradictions and significant burdens in the wrong areas, with often unintended consequences.

Actually, some time ago I participated in a discussion among CAIA committee members. One participant questioned whether regulators should not focus on protecting unsophisticated investors from venturing into alternative assets. He observed that regulatory philosophy is unfortunately not developing in this direction. The thrust of regulation like the AIFMD is to make alternative assets “safe,” which is almost comparable to the attempt to increase safety standards in Formula One by requiring to put a first aid kit and a spare tire on board of every racing car. This approach to regulate risk out of alternatives is counterproductive and almost absurd. Risks will continue to exist regardless, and this will just lead to a spiral of ever-tightening regulation. In my opinion, the right approach would be making sure that the investors in this asset class have the right skills, profile, processes, systems, experienced staff, and resources – to stay with the analogy, are qualified Formula One drivers instead of somebody with my driving skills.

Other participants feel very uncomfortable with regulating the kinds of investors who can access various investment products and saw this as a kind of discrimination. Because of their risk characteristics, strategies embraced by allegedly “sophisticated investors” would be off-limits to retail investors. Regulating differently according to type of investors does not strike me as radical as you see comparable approaches in many strands of life (for instance, driver licenses). My own bias is clearly private equity where attempts to make this asset class liquid and attract retail investors have arguably not met with great success. It is not about denying retail investors exposure to this asset class but about making sure that they involve intermediaries who know what they are doing and have sufficient skills, experience, and systems to deal with the risks. In any case, for the AIFMD and comparable regulatory initiatives it is still early days and the jury is still out.

Jason Scharfman Do you feel any countries' (or regions') regulatory regimes are better than others at balancing GP oversight without overburdening them from a compliance perspective?
Thomas Meyer My answer follows on from the previous question: Why focus on GP oversight and not become more stringent regarding limited partners (LPs)? The idea to focus on GPs, in my interpretation, stems from the perception that underperformance and failure is mainly caused by negligence and/or mistakes and that regulation is the right tool to address this. The interpretation of negligence and mistakes is arguing in hindsight, but for long-term-oriented investments change is inevitable – and in many situations change can be detrimental to investments without anybody at fault.

To maintain the integrity of the financial system does not seem convincing as a reason to regulate private equity as this asset class is hardly systemic. However, having grown from a few hundred private equity firms in the 1990s to by now about 10,000 private equity firms, more caution is clearly in order. Moreover, the financial industry is extremely innovative in finding loopholes and could certainly find ways to jump over the boundary to more liquid and systemic asset classes like hedge funds. So, it is sound to close all avenues to regulatory arbitrage and in this respect I personally welcome all-encompassing and sound regulation.

On the other hand, private equity as a niche area of the financial system never was the focus of regulation and more the troublesome exception. As a consequence, rules suitable to hedge funds are difficult to apply to private equity. Regulation also appears too much a reaction to the latest (perceived) scandal. Various regulatory initiatives overlap and there is no real architecture. For instance, in regard to private equity institutional investors are subject to Solvency II and Basel III, whereas the fund managers need to comply with the AIFMD, but these regulations do not talk to each other (or about the same thing).

Jason Scharfman Recently the US Securities and Exchange Commission (US SEC) has increasingly focused on scrutinizing previously accepted practices in areas such as GP fee acceleration and the overall expenses GPs pass through to LPs. Based on a lack of similar enforcement actions in other jurisdictions, do you feel there is less focus on these issues by European regulators? Is this a good or bad thing?
Thomas Meyer In many ways the US private equity market is still the most mature, sophisticated, and innovative, so it is no wonder that the Securities and Exchange Commission (SEC) often is the first regulator to focus on certain issues. On the other hand, private equity investors operate on a global basis, so practices quickly spread internationally and regulators worldwide sooner or later catch up with such trends. In any case, internationally operating US LPs are unlikely to continue accepting practices outside the United States that are no longer accepted in their own country.
Jason Scharfman Does such scrutiny in the United States benefit the overall transparency of the private equity industry?
Thomas Meyer The question of transparency in private equity continues to puzzle me as LPs always could ask GPs and – at least the experienced LPs – thus had full transparency, far more even than investors in publicly quoted companies. The private equity industry is “private” and legitimately exploits opportunities associated with non-transparency, so I question whether increased transparency and disclosure would be the solution.

I interpret many aspects of regulatory initiatives as the result of a crisis of trust where suspicion about financial actors has become routine. However, private equity is operating in environments where information is difficult to get, non-standardized, and difficult to understand and where its interpretation requires professional judgment and experience. Any disclosure is likely to trigger a cycle of follow-on questions and increasing suspicion. As the philosopher Onora O'Neill observed, public distrust had grown in the “very years in which transparency and accountability had been so avidly pursued.”

Jason Scharfman The year 2018 has ushered in a host of new financial regulations that influence the private equity industry, including MiFID II, GDPR, and PRIIPs, with the majority of new regulations being implemented in Europe. How do you feel GPs in Europe, and those influenced by these new rules, are responding?
Thomas Meyer These financial regulations aim to protect unsophisticated investors, which, as discussed before, may be the wrong policy avenue to take. In any case, the European GPs have, more or less grudgingly, accepted these regulations and the smaller players are searching for lowest cost and bare-minimum solutions. On the other hand, the large GPs even appear to embrace these regulatory initiatives as they have sufficient resources to deal with them and the complexity and effort to comply helps them to erect entry barriers that keep competition out. I fear that this development will accelerate and eventually lead to a fossilization of this asset class.
Jason Scharfman What advice would you have for LPs seeking to invest in managers influenced by this new regulation to ensure their GPs are operating in compliance?
Thomas Meyer In order to ensure their GPs' compliance with regulation LPs need to spend more effort on operational due diligence (ODD) and monitoring. In fact, the experienced LPs have always been doing this. This also has created a market for third-party AIFMs whose entire raison d'être is to assure the regulatory compliance on behalf of their clients.
Jason Scharfman Do you feel private equity managers and investors in regions with less restrictive regulations, such as Asia, are at an advantage compared to Europe and the United States?
Thomas Meyer As alternative assets could be considered as “experiments” and investment strategies aim to exploit inefficient and underexplored niches, in theory less restrictive regulation would be advantageous as it puts fewer obstacles in the way of such experimentation. However, many funds in Asia count on EU and US LPs. That requires them, in the case of the EU, to obtain individual country licenses (i.e. “passports”) before marketing their funds to European investors. So they have no choice and need to comply with regulation. Also the registration with the US SEC is perceived to be a high hurdle. Asia and comparable markets therefore do not necessarily offer a “less restrictive” fund environment because many funds in both places would like to raise funds globally. A private equity manager in, say, Vietnam goes to Luxembourg, Zurich, and New York and recognizes that local legal assistance is needed to raise funds in these locations. For the bigger private equity houses that have legal teams and experience in this, it is just another cost. For smaller GPs it becomes a burdensome and risky issue.
Jason Scharfman Do you feel GPs do a good job managing and disclosing conflicts of interest? Why or why not?
Thomas Meyer Experienced and in particular institutional investors understand the relevance of conflicts of interest. For instance, they increasingly demand that a limited partner advisory committee (LPAC) – an important approach to address this concern – is part of a private equity fund's structure. In my experience, it is rather an issue for emerging firms where moving from to club deals with friends and family to first institutional funds often comes with legacy conflicts of interest, albeit not on purpose. Later and once firmly established this potential decreases as GPs understand that they need to be vigilant and don't want to jeopardize their relationship with LPs.
Jason Scharfman Some LPs and regulators have raised objections with the model of a lack of management fee offset typically applied to GP operating partners (as compared to the offsets typically applied for GP employees serving as directors of underlying portfolio companies). What are your thoughts on this?
Thomas Meyer Private equity is about incentives and alignment of interests, without offsets for monitoring and transaction-related fees; for instance, investors are not paying anymore for performance. Here incentives get distorted and the alignment of interests gets weakened. In the extreme, this even can become a double charging for the same activities and services to LPs and portfolio companies. However, I wonder whether this is really something where the regulator should step in. It is rather a practice LPs should reject and experienced LPs will reject.
Jason Scharfman Increasingly in the United States, LPACs have been given more transparency and oversight responsibilities in a host of areas, including compliance. Do you feel similar trends have taken hold in Europe? Do you feel the growth of LPACs is a good development for the private equity industry?
Thomas Meyer With it becoming a global asset class also in Europe LPACs are increasingly becoming a feature of the private equity landscape. As the LPACs' role and responsibilities are clearly defined and as they are advising the GP particularly on conflict of interest–related issues, institutional investors see such committees are best practice. They increasingly will not invest in a private equity fund unless an LPAC is included in the fund's structure. On the other hand, smaller funds without institutional investors rarely have an LPAC (see also next question).
Jason Scharfman In the United States, venture funds and private equity funds below certain minimum asset sizes are subject to exemptions from registrations and operate in a compliance-light environment. Do you feel that this exemption is necessary for venture funds and smaller private equity funds? Why?
Thomas Meyer This, in my eyes, shows the major inconsistency of the approach taken by regulators in the United States but also in the EU. Such exemptions contradict one important purpose of the regulation, that is, to protect investors (the stated mission of the US SEC is to protect investors, maintain fair, orderly, and efficient markets, and facilitate capital formation). Smaller funds tend to attract smaller investors that are less well placed to exercise oversight. Typically also less experienced investors need more protection than institutional investors that predominantly invest in larger funds that also fall under stronger regulation.

One could also interpret this as relying on “regulated” LPs. During my work for the EIF in the early 2000s we were continuously asked by policymakers to promote practices and push for investor protection clauses with the VC funds under EIF management. Many of the practices we developed and introduced later resurfaced in the AIFMD. In my interpretation at the time, EIF, due to its domineering position in the European VC market, acted as a “quasi-regulator,” giving confidence to less experienced LPs to follow EIF's lead. This would be in line with a model for alternative assets where it is rather the LPs who have to meet standards and as experienced investors need to exercise proper care.

Jason Scharfman What advice would you have for investors who want to invest in these funds, but raise concerns about the less strict required compliance obligations of these types of funds?
Thomas Meyer Following on from the last point, such investors need to rely on their own team of skilled and experienced private equity professionals.
Jason Scharfman Many new funds are burdened by the high costs of building an initial compliance infrastructure at launch. What advice would you offer to a new venture fund being started with regard to dealing with these compliance costs?
Thomas Meyer In Europe the model of the third-party AIFM addresses these high costs. The Bank of New York suggested that full AIFMD compliance adds approximately US$300K to US$1M per annum to a GP's operating costs. The one-off setup costs are between $100K and $250K, the long delays for getting regulatory approval aside. A third-party AIFM can provide the substance needed for compliance with the AIFM – portfolio management and risk management professionals, systems, and procedures – much quicker and cheaper.
Jason Scharfman Are there any types of expenses that GPs used to pass along to LPs but no longer should? How do you feel the area of GP expense management will continue to evolve?
Thomas Meyer This is all about incentives and alignment of interests. It is the oversubscribed and established firms where LPs want to get in and thus tend to accept many fees, whereas the smaller and emerging players are faced with a much stronger push-back in this respect. It should be the other way around, but it comes down to supply and demand.
Jason Scharfman What advice would you offer for investors seeking to better model GP compliance risk into their overall portfolio management process?
Thomas Meyer When speaking about portfolio management and risk, I look at this from the perspective of taking necessary risks in order to get a higher financial return. Arguably when focusing on compliance and operational risks the perspective is different. Here it is rather the avoidance of problems with regulators and unfavorable reputation that matters. On the other hand, investors in private equity funds, say, a pension fund, should keep this in balance against underperformance as this is what really hurts pensioners. Looking at this from a purely financial perspective, the likelihood of compliance and operational risk–related events is not correlated between funds and thus less of a concern for investors with diversified portfolios.

At a certain point investors find this cheaper to diversify the impact of such risks away than paying higher management fees to funds in order to further reduce the probability of adverse events. This is what was reflected in a comment a managing director of a highly respected VC fund-of-funds made at a conference pre-2008 (those were the days…): “If we hear a GP talk about risk management, we walk away from the deal.” Two caveats: First, also compliance and operational risk–related events can be correlated, for instance, in cases where flawed valuation or risk models are widely accepted in the industry. To tackle this, regulators should avoid being too prescriptive – strict adherence to regulatory requirements can also result in complacency, lack of attention, and systemic risk. Second, high diversification leads to higher probability that potentially embarrassing compliance failures happen, like the proverbial terrorist that is getting through. However, rather than aiming for funds being failsafe, investors should find ways to deal with public anger, admittedly not an easy task nowadays.

Jason Scharfman There has been increased scrutiny of private equity valuation practices, as well as several regulatory enforcement actions in this area. How do you see GP valuation practices evolving in the future?
Thomas Meyer Regulation (again, the EU AIFMD is an important example) requires that there are appropriate and consistent procedures concerning the valuation of private equity assets put in place and that the valuation process is independent from, for instance, portfolio management and remuneration functions, often involving external valuation agents. Since the beginning of the 2000 valuation practices in private equity have made great progress. Notably the development of the International Private Equity and Valuation (IPEV) Guidelines has been a significant step forward and I expect that such guidelines will become the standard worldwide.

Having said this, finding value and pricing it is the business GPs are in and if they would be always right in their assessments, the private equity asset class would be without any risk. Arguably, the valuation is more of an issue for auditors, regulators, and investors who are concerned about financial reporting errors and fair-value measurements that cannot be supported. But a value is not equivalent to a price and valuations are by definition subjective, even more so in the thin market that characterizes private equity. In my various publications I put forward as one argument why in private equity and particularly in venture capital we mainly see self-liquidating fund structures is because valuations relate to a large degree to intangibles and can only be proven as “true” by exiting the investments and turning them into liquidity. My concern is that with recent regulatory initiatives related to valuation we will see allegations of misbehavior in fair-value measurements where actually no wrong-doing happened.

Moreover, there are often conflicting objectives associated with “fair” valuations. The IPEV Guidelines see fair value as the “price that would be received to sell an asset in an Orderly Transaction between Market Participants at the Measurement Date,” which is certainly the perspective GPs would take. LPs may be more interested in understanding how the investments are developing, that is, consistency of valuations over time. Here I have heard the argument that practices before 2000 (keeping values at cost and only writing them up after new capital rounds) made this easier for LPs as this disregarded market noise. Auditors and regulators, on the other hand, tend to have a conservative bias, but LPs are also concerned about safeguarding their assets and would certainly object to assets being exited at low prices in line with a conservative valuation but that jump in value subsequently.

Finally, as a previous risk manager I (and several others in the industry) disagree with the IPEV Guidelines view that the fair value of fund interests is based (as described in the Guidelines essentially equivalent) on the fund's attributable net asset value. An in-depth discussion of this point goes beyond the scope of this interview. Just one aspect: LPs are exposed to the uncertainty regarding timing and amounts of the fund's cash flow. From their perspective also, the fund's undrawn capital forms part of their exposure. When LPs commit to a fund, the fund has no net-asset-value (NAV) but forms a risk.

Jason Scharfman Do you see an eventual move toward LPs demanding third-party administration (as they do in the hedge fund industry)?
Thomas Meyer Ultimately it is a question of the cost/benefit relationship. While transactions in private equity are not as frequent as in the case of hedge funds, they are far less standardized and require a deep understanding of many different situations. This makes high-quality fund administration expensive, and only with economies of scale is this viable. This in combination with demands for timely and high-quality reporting, also to regulators, makes third-party administration a more sensible option from the LP perspective.
Jason Scharfman What trends do you see in European private equity compliance going forward?
Thomas Meyer While this was not the case only a few years ago, the private equity industry now is aware of compliance. It has recognized that something needs to be done and has moved toward better compliance practices. One important trend is an entirely new industry emerging around regulation, the third-party AIFMs as an example. On the other hand, the current move toward compliance was to a large degree motivated by the regulators' paranoia, ushering a wave of rules which addressed concerns relevant to hedge funds but not suitable and not meaningful for private equity. In Europe there is some hope that AIFMD II will take this lesson on board. Like in the case of the UCITS regulation, which was first very restrictive but over time became more open in regard to eligible assets and strategies to invest in, it is possible that the review will lead to a more reasonable regulation with more distinct rules for private equity that are more tailored for the asset class's specifics. I may be too optimistic here, as at the end of the day private equity is still small compared to the rest of the financial system and therefore it could take much longer before regulators feel the need to change anything.

11.2 BIOGRAPHY AND INTERVIEW WITH MATTHEW DEMATTEIS – INSTITUTIONAL LIMITED PARTNERS ASSOCIATION (ILPA)

Matthew DeMatteis is the Institutional Limited Partners Association's (ILPA's) Director of Research. His primary responsibilities include LP-focused research papers, the ILPA Private Markets Benchmark, and an annual LP compensation survey. Matthew also leads several ILPA best-practices initiatives, including the Fee Transparency Initiative, Reporting Best Practices, and Due Diligence Questionnaire. Prior to joining the organization in 2013, he was a director at LP Capital Advisors, where he managed their fund diligence, advisory, and fund monitoring/analytics services. Matthew received his undergraduate degree in finance from Syracuse University.

JasonScharfman Can you provide an introduction to ILPA and the organization's role in the private equity industry?
Matthew DeMatteis ILPA is the only global, member-driven association comprised solely of institutional investors in private equity, typically through fund structures. Our 450+ member organizations manage approximately $2 trillion in private equity assets under management. These institutional investors join ILPA for access to best-in-class networking opportunities, education programs, and research, as well as to advocate for industry-wide best practices, including compliance.
Jason Scharfman ILPA outlines three guiding principles to form an effective private equity partnership between LPs and GPs. These are alignment of interest, governance, and transparency. How do you feel these principles relate to the current state of private equity compliance? Can you provide examples?
Matthew DeMatteis Transparency and governance are the tools used by LPs to ensure that the GP remains aligned with the best interest of the fund. For example, through greater transparency into the fees charged by GPs, LPs can gain confidence that the GPs are complying with the terms of the fund's LPA. Additionally, an engaged LPAC that's empowered to provide feedback on GP conflicts of interest, like investment valuations, can help ensure that a GP complies with its internal policies.
Jason Scharfman What benefits do you feel the uniform reporting practices encouraged by the templates have for LPs seeking to evaluate GPs in the area of compliance? Similarly, how can GPs utilize these templates to more effectively communicate their compliance infrastructures with LPs?
Matthew DeMatteis One of the greatest benefits from the standardized formats for fee reporting, capital calls, and distributions is the improved accuracy and uniformity of an LP's internal records, which are used to monitor fund activity and compliance. Without accurate data, even the simplest tasks, like reconciling their remaining commitment to a fund, can be problematic. Furthermore, using standard reporting templates allows LPs to compare funds in a way that utilizes the same definitions – apples to apples, if you will. In terms of how GPs can better communicate their cost structure, we certainly feel our Reporting Template on fees, expenses, and carried interest provides a roadmap to the GP's operations. This includes the services provided (to both the fund and its investments) by affiliated entities and third parties, all of which can represent potential conflicts that must be addressed through oversight and sound compliance policies.
Jason Scharfman The feedback I've heard from certain LPs is that they want more transparency from GPs regarding potential conflicts of interest when they arise, but they also don't want to micromanage GPs. What advice would you have with them to develop further meaningful dialogues in this regard?
Matthew DeMatteis LPs are certainly not staffed, nor interested for that matter, to micromanage their GPs. If they were, they wouldn't invest in funds in the first place. To be efficient “managers of managers,” LPs must conduct thorough operational and legal due diligence during fundraising. They must be comfortable that the fund provisions and GP policies designed to address agency conflicts are clear and impactful. During the life of the fund, LPs should leverage scheduled touchpoints (AGMs and quarterly update calls) to monitor any potential conflicts that are identified during their due diligence. The time invested before and during the life of the fund can help minimize LP-involvement in higher-touch issues, such as GP removal.
Jason Scharfman Can you comment on the compliance roles you feel should be played by the limited partner operating committee? What are some best practices you would recommend in this area?
Matthew DeMatteis LPACs can be most impactful when they serve as a sounding board for GPs to seek guidance on sensitive matters of conflict (e.g. valuation, potential amendments). However, they should not be used as a substitute for LP-wide engagement or as a proxy for the interest of all investors.
Jason Scharfman Do you feel LPs have a responsibility to be actively involved in partnering with GPs to implement best practices in areas such as compliance and governance or instead does this responsibility lie primarily with GPs?
Matthew DeMatteis All LPs have a responsibility to inform GPs of best practices, push for the implementation of best practices, and periodically monitor the progress of any implementation. Any further, more hands-on level of involvement can be highly inefficient for an LP and should only be used as a measure of last resort.
Jason Scharfman Beyond being familiar with a fund's offering documents, what steps do you feel LPs should take to educate themselves about a specific GP's compliance practices? And what about larger private equity compliance best practices in general?
Matthew DeMatteis Best practices in ODD include: (i) submitting a thoughtful set of questions that seek to clarify the statements made in offering documents and (ii) conducting onsite visits (ante- and post-commitment) at GP offices, including one-on-one conversations with compliance officers. The finer points of ODD are addressed during the educational opportunities provided to ILPA members.
Jason Scharfman What issues in private equity compliance do you feel are the most important to LPs today?
Matthew DeMatteis Compliance with fee and waterfall provisions is top of mind. There are also two other growing areas of interest: (i) the trend of increasing reliance upon credit facilities by certain types of equity-focused funds and (ii) that GPs are implementing and adhering to strong HR-level policies, including those preventing and identifying sexual harassment in the workplace.
Jason Scharfman What areas of compliance do you feel present the biggest challenges for both LPs and GPs?
Matthew DeMatteis The increasingly complex nature of multiproduct GPs, including those managing multiple funds at once and those with dedicated teams focused on operating improvements at portfolio companies, has created significant potential conflicts and compliance challenges that LPs must be mindful of. As a result, GPs have been beset with numerous bespoke requests for additional transparency on the fees they've charged. The inefficiencies created by these LP requests were among the primary reasons for the development of our Reporting Template.

11.3 BIOGRAPHIES AND INTERVIEW WITH CLAIRE WILKINSON AND LUDOVIC PHALIPPOU

Claire Wilkinson: Ms. Wilkinson is a UK solicitor. She trained at Slaughter and May and spent 11 years in total there advising on corporate finance, public, and private M&A, capital markets and a broad range of company law matters. She then worked as general counsel for 11 years in various in-house roles in private equity and venture capital. During this time, she founded and chaired the Private Equity Lawyers Forum, a best-practice knowhow and training organization for in-house lawyers, and served on the Invest Europe Professional Standards Committee, the BVCA's Responsible Investment Committee, and co-chaired the Invest Europe Responsible Investment Roundtable. She has contributed to a number of publications on private equity and participated on numerous panels and at numerous conferences. She teaches the Invest Europe Private Equity Foundation course. She now works for Grantham, Mayo, Van Otterloo & Co., LLC. She graduated from the University of Durham in French and German and holds a postgraduate diploma in Risk, Governance and Compliance from the University of Manchester.

Ludovic Phalippou: Mr. Phalippou is author of the bestseller Private Equity Laid Bare, published by the CreateSpace Independent Publishing Platform on September 7, 2017. He is a tenured faculty member of the Said Business School at the University of Oxford. He specializes in the areas of private equity that are of interest to investors in that asset class, such as fee tracking, interest alignment, and return benchmarking. Named as one of the “40 Most Outstanding Business School Profs Under 40 in the World” in 2014, and as one of the 20 most influential individuals in private equity in Europe in 2016, Ludovic has strong links with senior practitioners in the industry, routinely speaks at practitioner conferences, and appears in the media internationally. Ludovic's research papers have been widely cited in academia, in the press, and in regulatory circles. He worked with a number of large institutional investors on their private equity investment decisions and benchmarking systems. At Oxford, Ludovic teaches “Asset Management” and “Private Equity.” Ludovic achieved a degree in Economics from Toulouse School of Economics; a Master in Economics and a Master in Mathematical Finance both from the University of Southern California; and a PhD in Finance from INSEAD.

Claire Wilkinson/Ludovic Phalippou Let us first provide context on the evolution of in-house lawyers and the compliance function in private equity houses. Prior to 2000, the largest fund in Europe was under €1 billion in committed capital. The headcount of PE houses was small in comparison to today's staffing levels and specialization of function within PE houses was relatively unknown outside of the then–obviously essential investment professional, finance, and investor relations spheres. PE houses were more concentrated geographically, both in terms of the location of the investment management teams and investment hunting-ground. Fundraising, although already complex and protracted by 2000, followed conventional and recognized legal routes with limited co-investment opportunities and more passive LPs. Growth in the industry after 2000 was a catalyst for specialist recruitment within the PE houses themselves. Legislative changes imposed on the industry also played a role in the growth of specialist recruitment of lawyers and compliance personnel. In the UK, the Financial Services and Markets Act of 2000 was a driver for change by creating a new regulatory framework. In 2002, this was followed by the Sarbanes–Oxley Act, which had an impact beyond the United States on corporate governance practices. In 2008, the Markets in Financial Instruments Directive was a further key piece of legislation affecting conduct of business in PE houses, and in 2014, the AIF Managers Directive led to further legal complexity in the wake of demands for increased reporting coupled with curbs on remuneration.

Lawyers in private practice law firms became engaged in work arising as a result of these increases in complexity in fundraising and legislative landscape and in deal size. These lawyers made themselves indispensable to PE management teams. As fund sizes grew and number of closings with differentiation in terms increased, limited partnership agreements (LPAs) and ancillary documents expanded. Simply managing side letters became a full-time job.

Jason Scharfman How do you feel institutional investors (i.e. pension funds, sovereign funds, etc.) today approach the issue of compliance at private equity funds they are considering committing capital to?
Claire Wilkinson/Ludovic Phalippou Track record and investment thesis are the conventional fundamental elements for an investment decision for any institutional investor. But we live in times where the basis for decisions and the decision-making process must be thoroughly documented. It is important to note that although called asset owners, the institutional investors committing to PE (LPs) are investing other people's money. As a result, they take a risk-averse view about the scrutiny they could face about their decisions. Due diligence into the compliance function has therefore become part of the overall review and paper-gathering exercise prior to investment. That said, the typically raised due diligence questions regarding compliance are frequently formulaic and can be seen as a bolt-on tire-kicking exercise rather than something meaningful. It is rare for an investor to ask follow-up questions on the compliance section of the due diligence questionnaire, or to ask to interview compliance personnel as part of due diligence.
Jason Scharfman Do you feel US, European, and Asian institutional allocators take different approaches in this regard?
Claire Wilkinson/Ludovic Phalippou Investors' due diligence into compliance prior to investment is less dependent on the geography of the investor than on investor type. For example, large sovereign wealth funds in Asian and the Middle East and US public pension plans have detailed questionnaires. Investment consultants operating worldwide, potentially with the desire to demonstrate their own value-add through the production of volumes of paperwork, request particularly detailed, and lengthy analysis. Industry bodies and practices transcend borders. For example, the ILPA, while North American in origin, now has members worldwide and is influential in standards setting for LPs.When responsible investment first became a hot topic, it is true that Northern Europeans led the way in making this an issue and this had a knock-on effect on the involvement of Legal and Compliance. So, at the margin, it could be argued that some elements of compliance and governance scrutiny were driven by Scandinavian and Dutch investors before the rest of Europe, Asia, and ultimately North America took up the cause.
Jason Scharfman What are your thoughts about how institutional investors can integrate an assessment of a GP's compliance function into their overall risk assessment and ongoing risk management processes?
Claire Wilkinson/Ludovic Phalippou Few LPs ask to interview the compliance officer and the general counsel (GC) on their own, or even at all as part of their pre-investment due diligence exercise. Few compliance officers and GCs of LPs actively interact with their counterparts in the GP – the communication takes place through outside counsel and through the IR teams and investment consultants. The industry is in a phase where the exercise of judgment through face-to-face meetings and a more interlocutory style of information exchange has been supplanted by the production and disclosure of reams of written information which may or may not be read and analyzed prior to investment but provides a thick paper security blanket.
Jason Scharfman Anecdotally, certain LPs have expressed concerns that they feel GPs are behind the curve in regard to rigorous industry-wide compliance regimes as compared to hedge funds. What are your thoughts on this?
Claire Wilkinson/Ludovic Phalippou Yes, this observation is valid. Pockets of excellence in compliance do exist in PE houses and there are some excellent individual practitioners, including in PE houses, that have experience in regulatory censure. There is just not a culture of compliance in PE. This is actually often presented as one of the benefits of PE: Companies they run focus on generating money instead of compliance-related paperwork and discussions. This mindset percolates to the PE house itself. There is much anecdotal evidence of senior management failing in their support of the compliance and legal function and failing to set the tone from the top. Lawyers and compliance folk are there to plug gaps and to do the work the investment professionals do not want to do. Few in-house lawyers and even fewer legally trained compliance officers are partners, few are board members, and few are invited to participate in fund marketing and decision-making bodies other than to perform the company secretarial function. All these factors indicate an industry sector where compliance is tolerated rather than embraced.
Jason Scharfman Can you comment on some of the differences you have seen develop between US and European private equity funds in regard to their approach to compliance? What implications do you feel this has had for the ways GPs approach compliance?
Claire Wilkinson/Ludovic Phalippou In my experience, US houses frequently exhibit a defensive style in answering LPs questions on compliance, very much adopting a minimal disclosure risk-averse and liability-limiting stance. European PE houses are more progressive and more open. GCs may have more power in the States, but Compliance has more power in Europe.
Jason Scharfman Specifically, how do you feel GPs are dealing with the wave of new and evolving European regulations such as MIFID 2, GDPR, and PRIIPs?
Claire Wilkinson/Ludovic Phalippou Compared to asset managers, PE houses have got away with it lightly on MIFID 2, GDPR, and PRIIPs. The AIF Managers Directive was a much bigger issue. The PE sector in general adapts to new regulation with typical creativity. PE houses have proven themselves to be adaptable to opening new offices, relocating, outsourcing, creating governance structures that meet regulatory demands, and developing the infrastructure to handle more complex reporting.
Jason Scharfman Do you feel GPs in general are responsive enough to institutional investors when they raise concerns in areas such as compliance and regulatory change impacting private equity funds?
Claire Wilkinson/Ludovic Phalippou LPs don't often raise these questions. From an in-house legal perspective, the lack of scrutiny could even be said to be disappointing. Where these concerns do arise, they are unlikely to be communicated directly to the in-house legal and compliance group. There are typically two responses. The first is to have the investor relations folk and CFO answer these queries, and the second response, where the compliance and legal functions are more integrated at senior management level, is to develop a written response in consultation with senior management, which is communicated through the investor relations function rather than through direct communication by the legal and compliance function with the institutional investor. This is not a satisfactory state of affairs and discourages transparency.
Jason Scharfman What are your thoughts on whether a GP should maintain a compliance function primarily consisting of in-house resources (such as an in-house chief compliance officer) versus a compliance function that is primarily outsourced to specialist compliance consultants?
Claire Wilkinson/Ludovic Phalippou We believe in integrating compliance into the culture of a firm and into the senior management function. Many disagree, mainly because of the cost, and specifically, who should pay for this increased compliance presence? Outsourced costs are easier to quantify and easier to expense to the fund. Ideally, there would be a Compliance/GC function which reports to the LPAC and is paid for from the fund (hence the LPs). It makes the Compliance/GC functions harder in some respects as performing a law-enforcement and whistleblowing role vis-a vis colleagues is difficult and there is an increased risk of concealment by the deal teams of issues that should be brought to Compliance's attention. A semi-independent compliance function would add robustness to the governance of a PE house. Note that many internal counsel and compliance officers behave in this manner already and tread a difficult tightrope diplomatically.
Jason Scharfman Do you feel a one-size-fits-all approach works for GP compliance?
Claire Wilkinson/Ludovic Phalippou No, but there are certainly common themes in almost every PE house. The regulator allows firms to adapt their compliance programs to suit the nature, scale, and complexity of that firm's business. GPs' compliance departments can leverage industry experience and apply it to their own model.
Jason Scharfman As compliance has become more resources intensive, increasingly the costs of developing a compliance infrastructure for a private equity firm have gone up. From both a risk management and capital allocation perspective, do you feel institutional investors penalize start-up or younger private equity firms as compared to larger firms that may benefit from economies of scale and lower compliance costs on a per-fund basis?
Claire Wilkinson/Ludovic Phalippou Large PE houses seem to be happy to see these barriers to entry persist and encourage these barriers by appointing increasingly specialized teams that only they can afford. Yet, the PE sector has enjoyed a relatively light touch from regulators and the costs of compliance are not prohibitive to start-ups.
Jason Scharfman What challenges do you find institutional investors most commonly face when approaching the issue of GP compliance?
Claire Wilkinson/Ludovic Phalippou LPs do not always have the access to the Compliance and Legal functions in the PE houses that they ought to have. However, few LPs are requesting this access, which deprives them of a valuable data source and safety valve. In addition, the Compliance and Legal function interface with institutional investors only through the investor relations or finance function and thus have imposed a degree of “party line” which is not conducive to full transparency and cooperation.
Jason Scharfman What are your thoughts on current attitudes of GPs toward the levels and disclosures of transaction fees?
Claire Wilkinson/Ludovic Phalippou In recent years, a wide set of people became aware of the practice by PE houses of invoicing and claiming expenses directly from their portfolio companies – for example, transaction fees. As PE houses are in control of these companies but the ultimate equity holder is someone else (LPs), the potential for conflicts of interest and abuse is obvious. As boards and the public were generally quite surprised by the existence of such a practice, let alone how widespread it was, LPs had to act. Most LPs nowadays monitor how much is being charged to their portfolio companies and ask for full rebates. That appeases their boards but does not really solve the root of the problem and we can therefore be concerned that related issues will persist. When this topic became prominent (2012–2013), it was rather surprising to hear several prominent GPs saying that, yes, most of us have charged fees like this for many years, in large amounts, with LPs having little information about it, but we now refrain from charging such fees, we have moved on, so let's not talk about it anymore. In other contexts there might have been some follow-up questions.
Jason Scharfman Do you feel LPs have been more vocal in expressing their concerns in this regard? Do you note any differences in US and European attitudes in this regard? Why?
Claire Wilkinson/Ludovic Phalippou LPs been more vocal with regard to disclosure of transaction fees and this matter has also been the subject of regulatory scrutiny and press coverage. PE houses on both sides of the Atlantic have had to respond to these concerns.
Jason Scharfman Recently financial regulators have placed more attention on fee practices such as GP monitoring of fee extension and fee acceleration. Do you feel this will have a positive effect for institutional private equity investors?
Claire Wilkinson/Ludovic Phalippou Transparency and alignment do matter to LPs. The problem is that the alignment is often weak. Management and GPs have financial incentives that are quite aligned; LPs and GPs do not. It is also important to bear in mind that GPs are creative and entrepreneurial, and these traits are also put at work when it comes to writing an LPA or interpreting it. Obviously, in principle, this creativity and entrepreneurial activity should not be to the detriment of transparency. In practice, it varies from one PE house to the other.
Jason Scharfman What are your thoughts on current LP attitudes to the practice of GPs not generally applying management fee offsets to GP operating partners, but they are applied to GP employees serving on underlying portfolio companies?
Claire Wilkinson/Ludovic Phalippou What fundamentally matters here is that the extent of the offsets are fully budgeted and disclosed prior to the fees being incurred. PE houses can add value to their underlying portfolio companies, but the basis of the cost of this intervention needs to be disclosed in advance to investors (if they are not included in the management fees).
Jason Scharfman Regulators have increasingly focused on the allocation of GP expenses. One example was the SEC action relating to Kohlberg Kravis Roberts & Co. LP (KKR), relating to broker fee expenses. Do you feel institutional investors' attitudes toward (i) these types of expenses and (ii) the oversight of their allocation among funds has changed based on these actions? Do you feel attitudes are different in the United States as compared to Europe?
Claire Wilkinson/Ludovic Phalippou This has always been important, but only large LPs were fully aware of the importance. As discussed earlier, it took a symbolic fine by the SEC to a famous GP (and the ensuing press coverage) to make everyone aware of the issue. Also, bodies such as ILPA and Invest Europe have been influential in setting global standards. There are no differences between Europeans and Americans. This is pretty much one market, they all read the same newspapers.
Jason Scharfman Are there any fund expenses that you feel institutional investors are increasingly skeptical of?
Claire Wilkinson/Ludovic Phalippou An investor should be skeptical of any lack of clarity, reticence, or any over-complexity in the presentation of fund expenses, whatever their nature. In some funds the amounts are extraordinary, and it is sometimes difficult to obtain a breakdown of the total amount. Also, the fact that these expenses are ex-post is problematic for any investor. Any expenses except the essential ones (legal and accounting) are to be analyzed with care. And even the essential ones need to be analyzed to make sure they are at arm's-length prices.
Jason Scharfman What advice would you have for institutional investors seeking to evaluate the compliance function at a private equity firm?
Claire Wilkinson/Ludovic Phalippou Ask to see the legal and compliance team alone. Ask open-ended questions about the culture of the firm and also quantitative questions about the number of training sessions, number of board meetings, strategy sessions, and involvement of the legal and compliance departments in the preparation of investment theses. Ask for the view of your own compliance folk and have them meet their counterparts to establish a dialogue.
Jason Scharfman The role of LPACs has increasingly expanded. What role do you feel LPACs should play from a compliance perspective? Do you feel attitudes about LPACs differ among institutional investors in the United States and Europe?
Claire Wilkinson/Ludovic Phalippou LPACs rarely demand to hear the General Counsel speak. This is an omission. LPACs should routinely be asking for a closed session with the head of legal or compliance. Note that LPACs can themselves comprise members with conflicts of interest without the same fiduciary duties as the GP toward the entire constituency of LPs. This is a danger to be monitored by any LP without an LPAC seat. Again, no difference between the United States and Europe.
Jason Scharfman How do you feel institutional investors can develop dialogues with GPs about compliance and regulatory matters outside of formal LPACs?
Claire Wilkinson/Ludovic Phalippou An institutional investor with its own in-house legal capability should be encouraging its legal team to network in the industry with GP legal representatives. LPs and GPs have many legal and compliance issues in common and an increase in dialogue can help with benchmarking and increased understanding. The Private Equity Lawyers Forum and the International Bar Association welcome members from both LP and GP communities. Invest Europe has an LP forum. All these initiatives promote transparency and professional standards.
Jason Scharfman US financial regulators have increasingly focused on the disclosure of conflicts of interest by GPs. What do you feel are current institutional investor attitudes toward whether GPs are doing a good job in this area?
Claire Wilkinson/Ludovic Phalippou There are bound to be pockets of unsatisfactory behavior. Also, conflicts of interest are not the sole preserve of GPs. LPs with co-investments, seats on the LPAC, and interests in series of funds have conflicts of interest of their own to manage. LPs do not seem to demonstrate their concerns with action.
Jason Scharfman Is there room for improvement beyond the standard disclosures in fund legal documents?
Claire Wilkinson/Ludovic Phalippou There is actually no mandatory industry-wide training requirement on the management of conflicts of interest. Invest Europe's Professional Standards Handbook gives excellent guidance on conflict management and disclosure. However, I think there is room for improvement in how the messages in the Handbook are disseminated within both LP and GP organizations.
Jason Scharfman What private equity compliance and regulatory trends do you see going forward?
Claire Wilkinson/Ludovic Phalippou Maybe a quasi-independent compliance function reporting to the LPAC or to the annual LPs meeting will appear. While compliance culture is hard to measure, an annual qualitative analysis of key compliance metrics would raise the profile of compliance both in the GPs and with the LPs. On the flipside, what I see all too easily happening is that senior management will delegate compliance window-dressing to a compliance function that meekly accepts the responsibility in return for a quiet life and a small percentage of the carried interest, to the detriment of all.
..................Content has been hidden....................

You can't read the all page of ebook, please click here login for view all page.
Reset
18.223.119.17